Bank of New York Mellon Corp increased its stake in shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) by 6.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 163,012 shares of the medical equipment provider’s stock after buying an additional 9,684 shares during the period. Bank of New York Mellon Corp’s holdings in Corindus Vascular Robotics were worth $214,000 as of its most recent SEC filing.

Shares of Corindus Vascular Robotics Inc (CVRS) opened at 1.66 on Thursday. Corindus Vascular Robotics Inc has a one year low of $0.40 and a one year high of $2.25. The stock has a 50 day moving average of $1.79 and a 200-day moving average of $1.25. The company’s market capitalization is $310.91 million.

Corindus Vascular Robotics (NYSEMKT:CVRS) last posted its earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $2.26 million during the quarter, compared to the consensus estimate of $3.10 million. Corindus Vascular Robotics had a negative return on equity of 181.63% and a negative net margin of 1,272.20%. On average, equities analysts expect that Corindus Vascular Robotics Inc will post ($0.21) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Corindus Vascular Robotics Inc (CVRS) Shares Bought by Bank of New York Mellon Corp” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/10/corindus-vascular-robotics-inc-cvrs-shares-bought-by-bank-of-new-york-mellon-corp.html.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a report on Monday, June 26th. BidaskClub lowered shares of Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a report on Monday, July 24th. ValuEngine lowered shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Cowen and Company set a $3.00 price objective on shares of Corindus Vascular Robotics and gave the stock a “buy” rating in a report on Wednesday. Finally, B. Riley restated a “buy” rating and issued a $3.00 price objective on shares of Corindus Vascular Robotics in a report on Wednesday, May 10th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $2.67.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Want to see what other hedge funds are holding CVRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corindus Vascular Robotics Inc (NYSEMKT:CVRS).

Institutional Ownership by Quarter for Corindus Vascular Robotics (NYSEMKT:CVRS)

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.